Category: MS Drug Therapies

Featured image for “Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (sanofi.com)”

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (sanofi.com)

April 17, 2024 Download PDF New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis…

Stuart Schlossman

Featured image for “Press Release: TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis”

Press Release: TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

Apr 18, 2024 PDF Version NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), announced that…

Stuart Schlossman

Featured image for “Apr 17, 2024 – Press Release: Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis”

Apr 17, 2024 – Press Release: Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis

Apr 17, 2024 EAST HANOVER, N.J., April 17, 2024 — Novartis today announced data from the ALITHIOS open-label extension study showing sustained…

Stuart Schlossman

Apr 16, 2024 – Press Release: Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Media / Press Releases Tuesday, Apr 16, 2024 Results from the Phase III study showed that subcutaneous (SC) injection was consistent with…

Stuart Schlossman

Viatris and Mapi Pharma Statement Regarding New Drug Application for GA Depot

Viatris Inc. has been informed that Mapi Pharma Ltd. has received a Complete Response Letter (CRL) regarding the New Drug…

Stuart Schlossman

Featured image for “‘You’re Fine.’ Why Delays in MS Diagnosis Matter.”

‘You’re Fine.’ Why Delays in MS Diagnosis Matter.

by Lisa Doggett Family & lifestyle medicine physician, UT Health MS and Neuroimmunology Center; Sr. Medical Director, Sagility; Author of Up…

Stuart Schlossman

Tyruko Vs. Tysabri for Multiple Sclerosis Explained by Neurologist

Tyruko is a Tysabri biosimilar which has been FDA approved for multiple sclerosis. But is Tyruko just as good as…

Stuart Schlossman

Tyruko vs. Tysabri for Multiple Sclerosis: 5 Similarities and Differences to Know

Written by Cassandra Pardini, PharmD, MS | Reviewed by Daphne Berryhill, RPh – Key takeaways: The landscape of multiple sclerosis (MS) treatment options has evolved substantially over…

Stuart Schlossman

Featured image for “Will Frexalimab replace the anti-CD20s?”

Will Frexalimab replace the anti-CD20s?

It is clear to me, and it should be clear to my colleagues, that anti-CD20 therapies have a limited shelf-life…

Stuart Schlossman

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS (sanofi.com)

 Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS Paris, February 15, 2024. The…

Stuart Schlossman

Categories

Latest Blog Posts